This podcast was developed by AMJ in collaboration with GSK and is sponsored by GSK. This information is scientific and non-promotional in nature, and intended for U.S. audiences.
Less than 20% of biologic-eligible patients with GINA Step 5 asthma receive biologic therapy.1,2 In this AMJ podcast, experts discuss how real-world gaps in initiation, access, and adherence can affect whether patients start, stay on, and sustain benefit from biologic therapy over time.
Listen to the full episode to explore:
- Key real-world data on biologic initiation and adherence
- Patient cases showing common barriers across the care pathway
- Practical ways to uncover the true burden of severe asthma
- The ‘Start, Stay, Sustain’ framework for patient-centered care
Speakers:
Justin Kwiatek1
Tom Corbridge2
- US Medical Affairs Lead, Respiratory Biologics, GSK, Philadelphia, Pennsylvania, USA
- US Senior Medical Director, Respiratory Biologics, GSK, Durham, North Carolina, USA
References
- Park J et al. Biologic underutilization and healthcare burden in US patients with Type 2 severe asthma. J Asthma Allergy. 2026;19:580937.
- Maselli DJ et al. Patient characteristics and social determinants of health influence adherence to biologic therapy for asthma. SEAAIS 80th Annual Meeting, October 23-26, 2025.
